BURLINGTON, Mass., Jan. 30 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced today that it will unveil two new fractional handpieces at the 66th Annual Meeting of the American Academy of Dermatology (AAD) in San Antonio, Texas from February 2nd to 4th. Management will be available at this time for investor demonstrations and to discuss Palomar's full line of products in booth #2121 at the Henry B. Gonzalez Convention Center.
Palomar's new Lux2940(TM) fractional ablative laser handpiece is a sophisticated, single-treatment skin resurfacing device which allows the practitioner to tailor the level of skin tightening based on the patient's needs. Three treatment modes are available: short pulse for pure ablation with the fastest treatment times and quickest recovery; long pulse for more coagulation around the ablation columns; and a dual mode for a short pulse / long pulse automatic sequence for deeper corrections. The Lux2940(TM) microfractional technology preserves portions of healthy tissue surrounding the treatment zone, fostering unprecedented rates of reepithelialization and lower patient downtime, with significantly less pain than traditional ablative laser procedures.
Palomar's other new handpiece, the Lux1440(TM) is a fractional, non- ablative skin resurfacing handpiece that operates much like the popular Lux1540(TM), but with faster treatment times. Specifically, licensed practitioners are performing effective full-face treatments in about 12 minutes. As compared to other skin resurfacing devices, the Lux1440(TM) is perfect for a series of "gentler" skin resurfacing treatments, where patient comfort is a priority and little to no downtime a must.
Both the Lux2940(TM) handpiece and the Lux1440(TM) handpiece operates with the StarLux(R) 500 Laser and Pulsed Light System, a single platform with a full suite of aesthetic applications including hair removal, leg vein clearance, acne management and pigmented lesion treatments, and fractional non-ablative skin resurfacing.
Chief Executive Officer Joseph P. Caruso commented, "We are very excited about these new product introductions, which not only reflect the advancement of Palomar technology, but compliment our existing suite of products. Fractional technology continues to provide superior results and now with both ablative and non-ablative options, patients are able to independently select a treatment modality that fits their lifestyle. Our desire to provide the best user experience, facilitated and supported by our ongoing investment in technology, is a primary driver for Palomar. We believe there is a great need for this technology and will continue to produce innovative and reliable products that meet the demands of our customers."
To reserve a time to meet with Palomar management and/or receive product demonstrations, please contact Palomar's Investor Relations department at 781-993-2411 or firstname.lastname@example.org.
About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the- counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has an agreement with The Gillette Company to develop and commercialize home-use, light-based devices for women for hair removal and an agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light- based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.
For more information on Palomar and its products, visit Palomar's website at http://www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations section of the website.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are based on the Company's current expectations,
plans, intentions, beliefs or predictions. These forward-looking statements
are neither promises nor guarantees, but involve risk and uncertainties
that may individually or mutually impact the matters herein, and cause
actual results, events and performance to differ materially from such
forward-looking statements. These risk factors include, but are not limited
to, results of future operations, technological difficulties in developing
or introducing new products, the results of future research, lack of
product demand and market acceptance for current and future products, the
effect of economic conditions, challenges in managing joint ventures and
research with third parties and government contracts, the impact of
competitive products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained for
future products and additional applications, the results of litigation,
including patent infringement lawsuits, difficulties in collecting
royalties, potential infringement of third-party intellectual property
rights, factors affecting the Company's future income and resulting ability
to utilize its NOLs, and/or other factors, which are detailed from time to
time in the Company's SEC reports, including the report on Form 10-K for
the year ended December 31, 2006 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these
forward- looking statements, which speak only as of the date hereof. The
Company undertakes no obligation to release publicly the result of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
Contacts: Kayla Castle
Investor Relations Manager
Palomar Medical Technologies, Inc.
|SOURCE Palomar Medical Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved